Emyria Ltd's (ASX:EMD) Dr Michael Winlo caught up with Proactive's Andrew Scott soon after announcing they've received firm commitments from sophisticated and strategic investors in a well supported $5 million placement. Lead broker Sixty Two Capital identified investors aligned with the company’s strategic focus to register new treatments that are backed by Emyria’s unique clinical data and intellectual property.
Emyria welcomes strong support for $5 million placement
